Improved pharmacokinetic and pharmacodynamic profiles of insulin analogues using InsuPatch, a local heating device. Issue 8 (November 2014)

• Record Type: Journal Article
• Authors: Landau, Zohar; Klonoff, David; Nayberg, Irina; Feldman, Dmitry; Levit, Shmuel Boris; Lender, Dan; Mosenzon, Ofri; Raz, Itamar; Wainstein, Julio
• Is Part Of: Diabetes/metabolism research and reviews. Volume 30:Issue 8(2014:Nov.)
• Page Start: 686
• Page End: 692
• Publication Date: 2014-11
• Subjects: Diabetes -- Periodicals; Metabolism -- Periodicals; 616.642
• DOI: 10.1002/dmrr.2536
• Languages: English
• ISSNs: 1520-7552

Abstract

<abstract abstract-type="main"> <title>Abstract</title> <sec id="dmrr2536-sec-0001" sec-type="section"> <title>Background</title> <p>Previous studies have shown that heating the insulin injection site may accelerate insulin absorption. We investigated the pharmacological profile of insulin administered with InsuPatch, a local skin‐heating device.</p> </sec> <sec id="dmrr2536-sec-0002" sec-type="section"> <title>Methods</title> <p>In this randomized, crossover study carried out in 56 subjects with type 1 diabetes treated with insulin pump [mean age 32 ± 13.5 years; 23 women; HbA<sub>1c</sub>:7.8 ± 0.9% (62 ± 10 mmol/mol) (mean+/−standard deviation)]. Euglycemic glucose clamps were performed after administration of 0.15 units/kg of short‐acting insulin analogues. Each subject underwent three clamp procedures: two with the InsuPatch device (day 1 and day 3) and one without the device (day 1 control). The primary endpoints were the following: (1) the change in the area under the curve (AUC) of insulin during the first 60 min post‐insulin bolus on day 1 with the InsuPatch device <italic>versus</italic> day 1 control and (2) parameters to assess the safety of using the device.</p> </sec> <sec id="dmrr2536-sec-0003" sec-type="section"> <title>Results</title> <p>The area under the curve of insulin during the initial 60 min (insulin AUC<sub>0–60</sub>) after insulin bolus was increased by 29.7 ± 7% on day 1 InsuPatch <italic>versus</italic> day 1 control (<italic>p</italic> < 0.01). Maximal post‐insulin bolus concentration was 57 mU/L on day 1 InsuPatch <italic>versus</italic> 47.6 mU/L on day 1 control (<italic>p</italic> < 0.01). On day 3 InsuPatch, insulin AUC<sub>0–60</sub> was increased by 27.9 ± 72% <italic>versus</italic> day 1 InsuPatch (<italic>p</italic> < 0.01). Maximal insulin concentration was 70.4 mU/L <italic>versus</italic> 57 mU/L, respectively (<italic>p</italic> = 0.05).</p> </sec> <sec id="dmrr2536-sec-0004" sec-type="section"> <title>Conclusions</title> <p>The use of the heating device upon administration of short‐acting insulin analogues in pump‐treated type 1 diabetic patients was found to enhance insulin absorption. This heating device may therefore serve to achieve better meal insulin coverage. Copyright © 2014 John Wiley & Sons, Ltd.</p> </sec> </abstract>